Zydus Cadila Healthcare Ltd.

Gujrat, India

Zydus Cadila Healthcare Ltd.

Gujrat, India
SEARCH FILTERS
Time filter
Source Type

Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Albany, NY, May 21, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027 Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives. The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines. Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA. In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities. Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.html The pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Albany, NY, May 21, 2017 --( PR.com )-- Tetanus is a frightening disease that has plagued mankind since ancient times. Market Research Hub (MRH) has recently broadcasted a pipeline study done on this bacterial disease and titled as “Tetanus - Pipeline Review, H1 2017.” This study examines comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Moreover, its pipeline analysis by companies involved in its therapeutic development is also mentioned in detail.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives.The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines.Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA.In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities.Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.htmlThe pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


Patel M.M.,Sudan University of Science and Technology | Bhuva S.D.,Veeda Clinical Research | Patel M.M.,Zydus Cadila Healthcare Ltd
Reviews in Analytical Chemistry | Year: 2015

An extensive survey of the literature published in various analytical and pharmaceutical chemistry-related journals have been conducted, and the instrumental analytical methods that were developed and used for the determination of proton pump inhibitors in bulk drugs, formulations, and biological fluids have been reviewed. This review covers the time period from 1990 to 2011 during which 80 analytical methods, including all types of spectrophotometric and chromatographic techniques were reported. High-performance liquid chromatography (HPLC) with ultra violet (UV) detection was found to be the technique of choice for many workers, and more than 50 methods were based on liquid chromatography (LC) and ultra violet (UV). A critical analysis of the reported data was carried out and the present state of the art of the analytical techniques for the determination of omeprazole, esomeprazole, pantoprazole, rabeprazole, dexrabeprazole, tenatoprazole, lansoprazole, and dexlansoprazole is discussed. © 2015 by De Gruyter.


Shafiq S.,Zydus Cadila Healthcare Ltd. | Shakeel F.,University of Benghazi | Talegaonkar S.,Jamia Hamdard University | Khar R.K.,Jamia Hamdard University | Ali M.,Jamia Hamdard University
Journal of Dispersion Science and Technology | Year: 2010

Ramipril is a very sensitive and unstable antihypertensive drug molecule. Marketed formulations of ramipril lead to decrease in its assay value due to mechanical stress, compression, manufacturing processes, excipients, storage conditions, heat, moisture, and alkaline pH. Therefore the purpose of the present study was to enhance its stability using nanoemulsion technique. In order to enhance its stability, pH degradation studies at room temperature were performed using different standard buffer solutions as an aqueous phase in the nanoemulsion formulation. Nanoemulsion formulation was prepared by aqueous phase titration method. Shelf life of nanoemulsion was determined using Arrhenius plot. The degradation of ramipril after 180 days of storage was significantly lowest in formulation of pH 5.0 as compared to other formulations. The shelf life of nanoemulsion formulation was found to be highest at refrigerator temperature (2.87 years). These results indicated that stability of ramipril can be enhanced in nanoemulsion formulation using standard buffer (pH 5.0) as an aqueous phase. © Taylor & Francis Group, LLC.


Shafiq S.,Zydus Cadila Healthcare Ltd. | Shakeel F.,University of Benghazi
Clinical Research and Regulatory Affairs | Year: 2010

The aim of the present investigations was to evaluate the capacity of a combination of Labrasol and Plurol oleique as surfactant and cosurfactant on self-nanoemulsification efficiency of ramipril nanoemulsion. Sefsol-218, Labrasol, Plurol oleique, and standard buffer solution (pH 5.0) were selected as oil phase, surfactant, cosurfactant, and aqueous phase, respectively. Nanoemulsion formulations of ramipril were developed by a spontaneous emulsification method. Pseudoternary phase diagrams were constructed to identify nanoemulsion zones of ramipril. Selected formulations were evaluated in terms of thermodynamic stability tests using centrifugation, heating-cooling cycles, and freeze-thaw stress test. Some formulations were found stable and other formulations were unstable upon thermodynamic stability tests. Thermodynamically stable formulations were taken for self-nanoemulsification efficiency test. All the selected formulations passed self-nanoemulsification test in grade E only but not in grades A and B. Because none of the formulations passed the self-nanoemulsification efficiency test in grades A and B, it was concluded that a combination of Labrasol and Plurol is not suitable as surfactant and cosurfactant, respectively, for oral or self-nanoemulsifying drug delivery system of ramipril. © 2010 Informa UK Ltd.


Ravish H.S.,Kempegowda Institute of Medical science KIMS | Vijayashankar V.,BGS Global Institute of Medical science | Madhusudana S.N.,National Institute of Mental Health and Neuro Sciences | Sudarshan M.K.,Kempegowda Institute of Medical science KIMS | And 5 more authors.
Human Vaccines and Immunotherapeutics | Year: 2014

The affordability to rabies vaccine for intramuscular administration in post exposure prophylaxis is a major constraint. Therefore, in countries, where there are financial constraints, World Health Organization recommends intradermal rabies vaccination that reduces the quantity and cost of vaccination. This study was done to evaluate the safety and immunogenicity of indigenously developed rabies vaccine (VaxiRab N) in comparison to a WHO recommended rabies vaccine (Rabipur) with demonstrated efficacy when administered by intradermal route using updated Thai Red Cross regimen. Eighty-six dog bite cases were randomly given either VaxiRab N (n = 43) or Rabipur (n = 43) as post exposure prophylaxis. The rabies virus neutralizing antibody concentrations on days 14, 28, 90, and 180 were tested by modified rapid fluorescent focus inhibition test. The geometric mean RVNA concentration of both the groups were compared using t- test and was found that, P value > 0.05 on all days, thus showing no significant difference between the 2 groups. The adverse drug events were also compared using Z-test and was found to be not statistically significant (Z = 1.476, P = 0.139). In conclusion, VaxiRab N was found to be safe and effective in post exposure prophylaxis by intradermal route and was similar to the WHO recommended rabies vaccine (Rabipur) of demonstrated efficacy. © 2014 Landes Bioscience.


Premkumar B.,JNTUH College of Engineering | Srinivasamurthy M.,Vignan Institute of Pharmaceutical Sciences | Rajagopal K.,Zydus Cadila Healthcare Ltd.
Biosciences Biotechnology Research Asia | Year: 2013

To study the clinical characteristics of rheumatoid arthritis (RA) patients attending the rheumatology unit in a private hospital The demographic characteristics, laboratory parameters, comorbidities, articular manifestations and pattern of prescriptions were studied from the case records. A total of 75 RA patients were studied. Female preponderance was observed and the ratio was found to be 3:1. The frequent laboratory measurements were found to be erythrocyte sedimentation rate (ESR), hemoglobin (Hb), and other hematological parameters. The articular manifestations were found to be knee, wrist, ankle, shoulder and elbow joints. The most common comorbidity was found to be hypertension and diabetes mellitus. The prescription pattern revealed the disease modifying antirheumatic drugs (DMARDs) as the first line drugs followed by steroids and non -steroidal anti-inflammatory drugs (NSAIDs). The first line DMARD was found to be methotrexate. The tendency of polypharmacy was more and the most combination was DMARD with a steroid and NSAID. The trend reveals aggressive therapy among rheumatologists. Frequent monitoring of adverse drug reactions like hepatic abnormalities for DMARDs and bone densitometry for oral glucocorticoids and drug interactions could further improve the quality of life of RA patients.


Nathani B.R.,P.A. College | Pandya K.S.,P.A. College | Jeni M.M.,P.A. College | Patel M.R.,Zydus Cadila Healthcare ltd
Der Pharma Chemica | Year: 2011

Some new N-[3-(2-Oxo-1, 2-dihydro-indol-3-ylidene-hydrazinocarbonyl)-benzyl]-nicotinamide (III) have been synthesised from different isatin derivatives (I) by condensing with N-(3-hydrazinocarbonylbenzyl) nicotinamide (II). Their chemical structures have been confirmed by IR, 1H NMR, Mass and by elemental analysis. Investigation of antimicrobial activity of compounds was done by the disk diffusion technique. Among the compounds tested, the compound with 5-F, 5-CH3 substitution showed the most favourable antimicrobial activity.


Maitreyi Z.,Institute of Pharmaceutical Education and Research | Amit K.,Zydus Cadila Healthcare Ltd
International Journal of Advances in Pharmaceutical Sciences | Year: 2010

The reverse phase high performance liquid chromatography (RP-HPLC) method of Atenolol and Hydrochlorothiazide is individually available in United State of Pharmacopoeia-27 (USP-27) but no reference is available for combined estimation of Atenolol and Hydrochlorothiazide in tablets formulation. The aim of our present work was to develop a precise and validated RP-HPLC method for the simultaneous determination of Atenolol and Hydrochlorothiazide in tablets formulation. The quantification was carried out by using Zorbax SB-CN (250 x 4.6 mm), 5μm column in isocratic mode with mobile phase, Water: Buffer: Methanol (50:35:15). The flow rate was 1.2 ml/min. The peak purity of Atenolol and Hydrochlorothiazide were 0.999 and 1.000 respectively. Ruggedness and robustness of method were performed and the percentage relative standard deviation (RSD) was found below 2.0%. The percentage recovery was found in the range of 98% to 102% at three different levels. Calibration curves were linear over studies ranges with correlation co-efficient found between the range of 0.99 to 1.00. Sample and standard solution stability study was performed over 21 h at room temperature and found stable. The percentage deviation was below 2.0%.


Zaveri M.,Institute of Pharmaceutical Education and Research | Khandhar A.,Zydus Cadila Healthcare Ltd
International Journal of Advances in Pharmaceutical Sciences | Year: 2010

The objective of this present work was to develop and validate analytical method for quantitative determination of Paracetamol and Etoricoxib in a tablet formulation and also the comparison of invitro data with reference dosage form. Chromatographic separations of the two drugs were analyzed on a Kromasil C18 column (25cm × 4.6mm, 5μm). The mobile phase constituted of Buffer: Acetonitirile with gradient program was delivered at the flow rate 1.0 mL/min. Detection was performed at 220 nm. Separation was completed within 20 min. Calibration curves were linear with coefficient correlation between 0.99 to 1.0 over a concentration range of 48 to 146 μg/mL of Paracetamol and 6 to 19 μg/mL for Etoricoxib respectively. The relative standard deviation (R.S.D) was found to be less than 2.0%. Analysis for dissolution study was also performed by Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) method. Difference factor (f1) were found to be 2.85 and 3.83 and similarity factor (f2) were found to be 73.514 and 68.961 for Paracetamol and Etoricoxib respectively. © arjournals.org, All rights reserved.


PubMed | Zydus Cadila Healthcare Ltd.
Type: Journal Article | Journal: Die Pharmazie | Year: 2010

The purpose of the present investigation was to evaluate the capacity of Labrasol as surfactant for self-nanoemulsification efficiency of ramipril nanoemulsion formulation. Based on the solubility profile of ramipril, Sefsol-218, Labrasol and Carbitol were selected as oil phase, surfactant and cosurfactant, respectively. Based on the stability profile of ramipril, standard buffer solution of pH 5.0 was selected as an aqueous phase for the development of ramipril nanoemulsion formulation. Nanoemulsion formulations of ramipril were developed using an aqueous phase titration method. Pseudoternary phase diagrams were constructed to identify the nanoemulsion region. Selected formulations were subjected to different thermodynamic stability tests using centrifugation, heating cooling cycles and freeze thaw cycles. The formulations which were stable at thermodynamic stability tests were taken for self-nanoemulsification efficiency test. No creaming, cracking, coalescence or phase inversion was observed on most of the formulations upon thermodynamic stability tests. All the formulations passed self-nanoemulsification tests in grade C, D and E but not in grade A and B. Because none of the formulation passed self-nanoemulsification efficiency test in grade A and B, it was concluded that Labrasol is not suitable as surfactant for oral or self nanoemulsifying drug delivery system of ramipril.

Loading Zydus Cadila Healthcare Ltd. collaborators
Loading Zydus Cadila Healthcare Ltd. collaborators